The present investigation examined whether daily smokers with posttraumatic stress disorder (PTSD), as compared to daily smokers with either anxiety psychopathology or no current Axis I psychopathology, have decreased success in the early phases of a self-guided smoking quit attempt. Participants were 140 daily smokers (81 women; M (age) = 29.5; SD = 11.9; range = 18-65 years); approximately one-third of the sample met criteria for current PTSD (n = 47), one-third met criteria for other current anxiety disorders (without PTSD; n = 33), and one-third did not meet criteria for any current Axis I disorder (n = 60). Consistent with prediction, membership in the PTSD group, compared to membership in the other anxiety disorders group and the group with no current Axis I psychopathology, was associated with increased risk of lapse during the first week following quit day. Additionally, daily smokers with PTSD and other anxiety disorders were at significantly increased risk of relapse during the first week post-cessation compared to persons without Axis I psychopathology. However, the PTSD group and the other anxiety disorders group did not differ from one another in terms of relapse. Results suggest that PTSD is associated with increased risk of smoking lapse and relapse compared to smokers with no current Axis I psychiatric problems, and increased risk of early smoking lapse but not relapse, as compared to those with other anxiety disorders. Findings provide novel evidence that PTSD, and perhaps anxiety disorders more generally, may be important factors in reducing the odds of successful unaided quit attempts in the early phases of cessation.

Chronic pain and posttraumatic stress disorder (PTSD) are disabling conditions that affect biological, psychological, and social domains of functioning. Clinical research demonstrates that patients who are affected by chronic pain and PTSD in combination experience greater pain, affective distress, and disability than patients with either condition alone. Additional research is needed to delineate the interrelated pathophysiology of chronic pain and PTSD, with the goal of facilitating more effective therapies to treat both conditions more effectively; current treatment strategies for chronic pain associated with PTSD have limited efficacy and place a heavy burden on patients, who must visit various specialists to manage these conditions separately. This article focuses on neurobiological factors that may contribute to the coprevalence and synergistic interactions of chronic pain and PTSD. First, we outline how circuits that mediate emotional distress and physiological threat, including pain, converge. Secondly, we discuss specific neurobiological mediators and modulators of these circuits that may contribute to chronic pain and PTSD symptoms. For example, neuropeptide Y, and the neuroactive steroids allopregnanolone and pregnanolone (together termed ALLO) have antistress and antinociceptive properties. Reduced levels of neuropeptide Y and ALLO have been implicated in the pathophysiology of both chronic pain and PTSD. The potential contribution of opioid and cannabinoid system factors also will be discussed. Finally, we address potential novel methods to restore the normal function of these systems. Such novel perspectives regarding disease and disease management are vital to the pursuit of relief for the many individuals who struggle with these disabling conditions.

The present investigation compared 123 community-recruited daily smokers with posttraumatic stress disorder (PTSD), panic disorder (PD), nonclinical panic attacks (PA), or no current Axis I psychopathology (controls; C) in terms of nicotine dependence, smoking rate, quit history, severity of symptoms during past quit attempts, and motivation for and expectancies about smoking. No differences were observed between groups in regard to smoking rate or nicotine dependence. The PTSD group reported making more lifetime quit attempts than the other groups, and the PTSD and PD groups perceived more severe symptoms during past quit attempts. The PD and PTSD groups reported greater motivation to smoke to reduce negative affect. Individuals with PTSD endorsed a stronger expectation that smoking would alleviate negative mood states and would produce negative consequences. Overall, results suggest that smokers with PD or PTSD differ from other smoking groups in a number of clinically significant ways. Keywords Smoking; Panic; PTSD; Anxiety Disorders; Smoking Motives and ExpectanciesCorrespondence concerning this article should be addressed to Michael J. Zvolensky, Ph.D. at The University of Vermont, Department of Psychology, 2 Colchester Avenue, John Dewey Hall, Burlington,. Electronic mail may be sent to Michael.Zvolensky@uvm.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. There is an increasing empirical recognition that tobacco use and dependence are elevated among those with psychopathology compared to those without psychiatric conditions (Kalman, Morissette, & George, 2005). For example, persons with, relative to those without, psychiatric disorders are approximately twice as likely to be current smokers (Lasser et al., 2000). Moreover, it is estimated that although smokers with psychiatric disorders represent approximately 20% of persons in the United States (U.S.), they consume over 40% of the cigarettes in the nation (Lasser et al., 2000). Such high rates of smoking among those with psychiatric disorders may play a clinically significant role in the high rates of diagnostic comorbidity and mortality observed in people with psychiatric disorders (Kalman et al., 2005). NIH Public AccessRecent studies have found important linkages between smoking and certain anxiety disorders (Feldner, Babson, & Zvolensky, 2007a;Morissette, Tull, Gulliver, Kamholz, & Zimering, 2007;Patton, Carlin, Coffey, Wolfe, Hibbert, & Bowes, 1998; Zvolensky, Feldner, LeenFeldner, & McLeish, 2005 (Beckham et al., 1995;Breslau et al., 2003;Buckley et al., 2004;Feldner et al., 2007a). Recent contr...

The current report presents the underlying rationale and components of an interoceptive exposure-based smoking cessation treatment for anxiety-sensitive smokers. The intervention was pilot-tested on three (female) daily smokers with moderate to high levels of nicotine dependence and high levels of anxiety sensitivity. Results indicated meaningful therapeutic gains in smoking outcome and theoretically expected changes in anxiety sensitivity, distress tolerance, and negative as well as positive affective states. Overall, the present case series highlights a potentially promising way to integrate interoceptive exposure-based treatment with standard smoking cessation treatment for smokers high in anxiety sensitivity. From a treatment development perspective, these case-series data suggest that future study of this intervention in a large-scale (controlled) clinical trial is indicated.

The present investigation examined the relationships between anxiety sensitivity and motivation to quit smoking, barriers to smoking cessation, and reasons for quitting smoking among 329 adult daily smokers (160 females; M (age) = 26.08 years, SD = 10.92). As expected, after covarying for the theoretically relevant variables of negative affectivity, gender, Axis I psychopathology, nonclinical panic attack history, number of cigarettes smoked per day, and current levels of alcohol consumption, we found that anxiety sensitivity was significantly incrementally related to level of motivation to quit smoking as well as current barriers to quitting smoking. Partially consistent with the hypotheses, after accounting for the variance explained by other theoretically relevant variables, we found that anxiety sensitivity was significantly associated with self-control reasons for quitting smoking (intrinsic factors) as well as immediate reinforcement and social influence reasons for quitting (extrinsic factors). Results are discussed in relation to better understanding the role of anxiety sensitivity in psychological processes associated with smoking cessation.